Loading...
| A01169 | Pages: 230 | Mar 2020 | 6957 Views | | |
| Author(s) : Sanjivan Gill & Onkar Sumant | Tables: 91 | Charts: 63 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Osteoporosis Drugs Market
Request Now !The global osteoporosis drugs market accounted for $7,657 million in 2018, and is expected to reach $10,479 million by 2026, registering a CAGR of 3.9% from 2019 to 2026.
Osteoporosis is defined as a medical condition, which is characterized by low density and quality of bones in humans. Furthermore, the bones become porous in this medical condition, which makes them more fragile and, in turn, prone to factures. The condition is caused by over production of the hormone called as parathyroid. The condition can lead to severe fractures, which can have deleterious effects on the health of patient. Therefore, the condition requires treatment, which includes the use of osteoporosis drugs. Some of the drugs available in the market include bisphosphonates selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, and RANK ligand inhibitors. These drugs are administered through different routes in the body such as orally or intravenously.
Get more information on this report : Request Sample Pages
The major factor that contributes to the growth of osteoporosis drugs market include rise in prevalence of osteoporosis. Furthermore, other factors that boost the growth of the osteoporosis drugs market are surge in geriatric population across the globe and rise in adoption of sedentary lifestyle worldwide. However, side effects of osteoporosis drugs and the time-consuming drug approval process hamper the growth of osteoporosis drugs market. Conversely, high growth potential in developing economies is expected to offer lucrative opportunities during the forecast period.
Osteoporosis Drugs Market Segmentation
The osteoporosis drugs market size is studied on the basis of drug class, route of administration, and region to provide a detailed assessment of the market. On the basis of drug class, the market is segmented into bisphosphonates, selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. By route of administration, it is segregated into oral, injectable, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
Segment Review
By product, the bisphosphonates acquired the major share of osteoporosis drugs market in 2018, owing to increase in investment in R&D of advanced novel bisphosphonates drugs by major players. Furthermore, bisphosphonates are commonly prescribed drugs for the treatment of osteoporosis, which boosts the growth of the market. However, the rank ligand inhibitors segment is expected to exhibit fastest growth rate during the forecast period, owing to the fact that these drugs are used to treat bone metastasis by acting as a chemoattractant to bone for tumor cells that express its receptor, RANK. Thus, the inhibition of the RANKL-RANK pathway serves as an ideal treatment for the bone metastasis.
Get more information on this report : Request Sample Pages
By route of administration, the oral segment acquired the major share of the osteoporosis drugs market, owing to abundant availability of medications, which are available as oral drugs in the market. Conversely, the injectable segment is expected to grow at the fastest CAGR during the forecast period, owing to factors such as rise in need for drugs, which exhibit improved bioavailability rapid mode of action.
Get more information on this report : Request Sample Pages
Region wise, North America accounted for the major share in 2018, and is expected to continue this trend, owing to easy availability of osteoporosis drugs. Moreover, surge in incidence of osteoporosis contributes toward the growth of this market. On the contrary, Asia-Pacific is expected to register the fastest growth during the forecast period attributed to increase in awareness regarding the use of osteoporosis drugs. Moreover, the constantly evolving life science industry drives the growth of the market in the developing economies such as India, China, and Malaysia.
Get more information on this report : Request Sample Pages
The global osteoporosis drugs market is highly competitive, and the prominent players in the market have adopted various strategies to garner maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Amgen Inc., F. Hoffmann-La Roche AG, Radius Health, Inc., Merck & Co. Inc., Novartis International AG (Sandoz), Pfizer Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Top player positioning
3.2.1. Top investment pockets
3.3. Porter's five force analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of osteoporosis
3.4.1.2. Rapid increase in aging population
3.4.1.3. Adoption of sedentary lifestyle
3.4.2. Restraints
3.4.2.1. Side effects of osteoporosis drugs
3.4.2.2. Stringent regulatory drug approval process
3.4.3. Opportunity
3.4.3.1. High growth prospects in emerging markets
3.4.4. Impact analyses
CHAPTER 4: OSTEOPOROSIS DRUGS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Bisphosphonates
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Selective estrogen inhibitors modulator
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Parathyroid hormone therapy
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Calcitonin
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Rank ligand inhibitors
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Others
4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country
CHAPTER 5: OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Injectable
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Others
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: OSTEOPOROSIS DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. North America osteoporosis drugs market, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by drug class
6.2.2.1.2. U.S. market size and forecast, by route of administration
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by drug class
6.2.2.2.2. Canada market size and forecast, by route of administration
6.2.2.3. Mexico
6.2.2.3.1. Mexico market size and forecast, by drug class
6.2.2.3.2. Mexico market size and forecast, by route of administration
6.2.3. North America market size and forecast, by drug class
6.2.4. North America market size and forecast, by route of administration
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Europe osteoporosis drugs market, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by drug class
6.3.2.1.2. Germany market size and forecast, by route of administration
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by drug class
6.3.2.2.2. France market size and forecast, by route of administration
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by drug class
6.3.2.3.2. UK market size and forecast, by route of administration
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by drug class
6.3.2.4.2. Italy market size and forecast, by route of administration
6.3.2.5. Spain
6.3.2.5.1. Spain market size and forecast, by drug class
6.3.2.5.2. Spain market size and forecast, by route of administration
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe market size and forecast, by drug class
6.3.2.6.2. Rest of Europe market size and forecast, by route of administration
6.3.3. Europe market size and forecast, by drug class
6.3.4. Europe market size and forecast, by route of administration
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Asia-Pacific osteoporosis drugs market, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by drug class
6.4.2.1.2. Japan market size and forecast, by route of administration
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by drug class
6.4.2.2.2. China market size and forecast, by route of administration
6.4.2.3. Australia
6.4.2.3.1. Australia market size and forecast, by drug class
6.4.2.3.2. Australia market size and forecast, by route of administration
6.4.2.4. India
6.4.2.4.1. India market size and forecast, by drug class
6.4.2.4.2. India market size and forecast, by route of administration
6.4.2.5. South Korea
6.4.2.5.1. South Korea market size and forecast, by drug class
6.4.2.5.2. South Korea market size and forecast, by route of administration
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific market size and forecast, by drug class
6.4.2.6.2. Rest of Asia-Pacific market size and forecast, by route of administration
6.4.3. Asia-Pacific market size and forecast, by drug class
6.4.4. Asia-Pacific market size and forecast, by route of administration
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. LAMEA osteoporosis drugs market, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil market size and forecast, by drug class
6.5.2.1.2. Brazil market size and forecast, by route of administration
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia market size and forecast, by drug class
6.5.2.2.2. Saudi Arabia market size and forecast, by route of administration
6.5.2.3. South Africa
6.5.2.3.1. South Africa market size and forecast, by drug class
6.5.2.3.2. South Africa market size and forecast, by route of administration
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA market size and forecast, by drug class
6.5.2.4.2. Rest of LAMEA market size and forecast, by route of administration
6.5.3. LAMEA market size and forecast, by drug class
6.5.4. LAMEA market size and forecast, by route of administration
CHAPTER 7: COMPANY PROFILES
7.1. Amgen Inc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. Eli Lilly and Company
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. F. HOFFMANN-LA ROCHE LTD.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. Radius Health, Inc.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. Merck & Co. Inc.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. Novartis International AG (Sandoz)
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. Pfizer Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Sun Pharmaceutical Industries Ltd.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. Takeda Pharmaceutical Company Limited
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. Teva Pharmaceutical Industries Ltd.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL OSTEOPOROSIS DRUGS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION) 57
TABLE 02. BISPHOSPHONATES MARKET , BY REGION, 2018–2026 ($MILLION) 59
TABLE 03. SELECTIVE ESTROGEN INHIBITORS MODULATOR MARKET, BY REGION, 2018–2026 ($MILLION) 63
TABLE 04. PARATHYROID HORMONE THERAPY MARKET, BY REGION, 2018–2026 ($MILLION) 67
TABLE 05. CALCITONIN MARKET, BY REGION, 2018–2026 ($MILLION) 71
TABLE 06. RANK LIGAND INHIBITORS MARKET, BY REGION, 2018–2026 ($MILLION) 75
TABLE 07. OTHER OSTEOPOROSIS DRUGS MARKET, BY REGION, 2018–2026 ($MILLION) 79
TABLE 08. OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION) 82
TABLE 09. ORAL OSTEOPOROSIS DRUGS MARKET, BY REGION, 2018–2026 ($MILLION) 85
TABLE 10. INJECTABLE OSTEOPOROSIS DRUGS MARKET, BY REGION, 2018–2026 ($MILLION) 89
TABLE 11. OSTEOPOROSIS DRUGS MARKET FOR OTHER ROUTE OF ADMINISTRATION, BY REGION, 2018–2026 ($MILLION) 92
TABLE 12. OSTEOPOROSIS DRUGS MARKET REVENUE, BY REGION, 2018–2026 ($MILLION) 96
TABLE 13. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, 2018–2026 ($MILLION) 98
TABLE 14. U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 101
TABLE 15. U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION) 102
TABLE 16. CANADA OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 104
TABLE 17. CANADA INFLUENZA TREATMENT OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION) 105
TABLE 18. MEXICO OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 107
TABLE 19. MEXICO OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION) 108
TABLE 20. NORTH AMERICA OSTEOPOROSIS DRUGS REVENUE, BY DRUG CLASS, 2019–2026($MILLION) 110
TABLE 21. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026($MILLION) 111
TABLE 22. EUROPE OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, 2018–2026 ($MILLION) 115
TABLE 23. GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 117
TABLE 24. GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION) 118
TABLE 25. FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 120
TABLE 26. FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION) 121
TABLE 27. UK OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 123
TABLE 28. UK OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION) 124
TABLE 29. ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 127
TABLE 30. ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION) 128
TABLE 31. SPAIN OSTEOPOROSIS DRUGS REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 130
TABLE 32. SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION) 131
TABLE 33. REST OF EUROPE OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 133
TABLE 34. REST OF EUROPE OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION) 134
TABLE 35. EUROPE OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION) 136
TABLE 36. EUROPE OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026($MILLION) 137
TABLE 37. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, 2018–2026 ($MILLION) 140
TABLE 38. JAPAN OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 142
TABLE 39. JAPAN OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION) 144
TABLE 40. CHINA OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 146
TABLE 41. CHINA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION) 147
TABLE 42. AUSTRALIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 149
TABLE 43. AUSTRALIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION) 150
TABLE 44. INDIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 152
TABLE 45. INDIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION) 153
TABLE 46. SOUTH KOREA OSTEOPOROSIS DRUGS REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 156
TABLE 47. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION) 157
TABLE 48. REST OF ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 159
TABLE 49. REST OF ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION) 160
TABLE 50. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION) 162
TABLE 51. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026($MILLION) 163
TABLE 52. LAMEA OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, 2018–2026 ($MILLION) 166
TABLE 53. BRAZIL OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 169
TABLE 54. BRAZIL OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026 ($MILLION) 170
TABLE 55. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 172
TABLE 56. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION) 173
TABLE 57. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 176
TABLE 58. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION) 177
TABLE 59. REST OF LAMEA OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION) 179
TABLE 60. REST OF LAMEA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2019–2026 ($MILLION) 180
TABLE 61. LAMEA OSTEOPOROSIS DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION) 182
TABLE 62. LAMEA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2019–2026($MILLION) 183
TABLE 63. AMGEN: COMPANY SNAPSHOT 185
TABLE 64. AMGEN: PRODUCT SEGMENT 186
TABLE 65. AMGEN: PRODUCT PORTFOLIO 187
TABLE 66. LILLY: COMPANY SNAPSHOT 189
TABLE 67. LILLY: OPERATING SEGMENTS 190
TABLE 68. LILLY: PRODUCT PORTFOLIO 190
TABLE 69. ROCHE: COMPANY SNAPSHOT 193
TABLE 70. ROCHE: OPERATING SEGMENTS 194
TABLE 71. ROCHE: PRODUCT PORTFOLIO 195
TABLE 72. RADIUS: COMPANY SNAPSHOT 198
TABLE 73. RADIUS: PRODUCT PORTFOLIO 199
TABLE 74. MERCK: COMPANY SNAPSHOT 201
TABLE 75. MERCK: OPERATING SEGMENTS 202
TABLE 76. MERCK: PRODUCT PORTFOLIO 203
TABLE 77. NOVARTIS AG: COMPANY SNAPSHOT 205
TABLE 78. NOVARTIS: OPERATING SEGMENTS 206
TABLE 79. NOVARTIS AG: PRODUCT PORTFOLIO 207
TABLE 80. PFIZER: COMPANY SNAPSHOT 211
TABLE 81. PFIZER: OPERATING SEGMENTS 212
TABLE 82. PFIZER: PRODUCT PORTFOLIO 212
TABLE 83. SUN PHARMA: COMPANY SNAPSHOT 216
TABLE 84. SUN PHARMA: OPERATING SEGMENTS 216
TABLE 85. SUN PHARMA: PRODUCT PORTFOLIO 217
TABLE 86. TAKEDA: COMPANY SNAPSHOT 219
TABLE 87. TAKEDA: OPERATING SEGMENTS 220
TABLE 88. TAKEDA: PRODUCT PORTFOLIO 220
TABLE 89. TEVA: COMPANY SNAPSHOT 223
TABLE 90. TEVA: OPERATING SEGMENTS 224
TABLE 91. TEVA: PRODUCT PORTFOLIO 224
LIST OF FIGURES
FIGURE 01. GLOBAL OSTEOPOROSIS DRUGS MARKET SEGMENTATION
FIGURE 02. TOP PLAYER POSITIONING, 2018
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTION
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. LOW THREAT OF NEW ENTRANTS
FIGURE 09. IMPACT ANALYSES
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF BISPHOSPHONATES MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF SELECTIVE ESTROGEN INHIBITORS MODULATOR MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PARATHYROID HORMONE THERAPY MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CALCITONIN MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF RANK LIGAND INHIBITORS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF OTHER OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ORAL OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF INJECTABLE OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF OSTEOPOROSIS DRUGS MARKET FOR OTHER ROUTE OF ADMINISTRATION, BY COUNTRY, 2018 & 2026 (%)
FIGURE 19. U.S. OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 20. CANADA OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 21. MEXICO OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 22. COMPARISON OF MALE GERIATRIC POPULATION IN EUROPEAN COUNTRIES, 2017 (MILLION)
FIGURE 23. GERMANY OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 24. FRANCE OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 25. UK OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 26. ITALY OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 27. SPAIN OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 28. REST OF EUROPE OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 29. JAPAN OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 30. CHINA OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 31. AUSTRALIA OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 32. INDIA OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 33. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 34. REST OF ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 35. BRAZIL OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 36. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 37. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 38. REST OF LAMEA OSTEOPOROSIS DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 39. AMGEN: NET SALES, 2016–2018 ($MILLION)
FIGURE 40. AMGEN: REVENUE SHARE BY REGION, 2018(%)
FIGURE 41. LILLY: NET SALES, 2016–2018 ($MILLION)
FIGURE 42. LILLY: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 43. LILLY: REVENUE SHARE BY REGION, 2018(%)
FIGURE 44. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 45. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 46. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 47. RADIUS: NET SALES, 2016–2018 ($MILLION)
FIGURE 48. MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 49. MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 50. MERCK: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 51. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 52. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 53. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 54. PFIZER: REVENUE, 2016–2018 ($MILLION)
FIGURE 55. PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 56. PFIZER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 57. SUN PHARMA: NET SALES, 2016–2018 ($MILLION)
FIGURE 58. SUN PHARMA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 59. TAKEDA: NET SALES, 2016–2018 ($MILLION)
FIGURE 60. TAKEDA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 61. TAKEDA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 62. TEVA: NET SALES, 2016–2018 ($MILLION)
FIGURE 63. TEVA: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
Osteoporosis drugs are utilized in the treatment of osteoporosis, which is marked by the presence of weak and porous bones. In addition, osteoporosis requires immediate treatment as the weak bones are highly prone to fractures which can lead to serious harmful effects on the health of the patient. The condition is caused due to the overproduction of hormone parathyroid. Some drugs which are available in the market for the treatment of osteoporosis include bisphosphonates selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others.
The utilization of osteoporosis drugs has witnessed a significant growth, owing to surge in incidence of osteoporosis across the globe. The other factors that propel the utilization of different osteoporosis drugs include surge in healthcare expenditure and rise in R&D investments related to osteoporosis drugs. Conversely, stringent governmental regulations related to approval of osteoporosis is a key factor that restricts the growth of the market. However, high market potential offered by developing economies is expected to present lucrative opportunities for the key players during the forecast period.
A. The total market value of osteoporosis drugs market is $ 7,656.97 million in 2018.
A. The forcast period for osteoporosis drugs market is 2019 to 2026
A. The market value of osteoporosis drugs market in 2019 is $8,014.64 million.
A. The base year is 2018 in osteoporosis drugs market
A. Top companies such as, Novartis International AG (Sandoz), Amgen Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Eli Lilly And Company held a high market position in 2018. These key players held a high market postion owing to the strong geographical foothold in different regions.
A. Rank ligand inhibitors segment is the most influencing segment owing to rise in prevelance of bone cancer as these type of drugs are used in the treatment of bone metastasis. Furthemore, surge in the awareness towards early diagnosis of cancer is another factor that fuels the growth of the market.
A. The major factor that fuels the growth of the global osteoporosis drugs market is the prevalence of osteoporosis in the widespread elderly population. This lead to surge in demand for drugs used to treat the medical condition.
A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 4.4%. This is due to the improvements in health standards, surge in disposable incomes, and advancements in technology for the development of osteoporosis drugs.
A. Osteoporosis drugs are defined as therapeutic agents which are utilized in the treatment of osteoporosis. Furthermore, osteoporosis is a serious medical condition which is associated with the presence of fragile bones
A. Osteoporosis drugs are employed in slowing down the bone brekage and rebuild the damaged bones. Furthemore, there are different type of osteoporosis drugs present in the market such as bisphosphonates, calcitonin, rank ligand inhibitors and others
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
